ATE350016T1 - Bicalutamid enthaltende pharmazeutische zusammensetzung - Google Patents

Bicalutamid enthaltende pharmazeutische zusammensetzung

Info

Publication number
ATE350016T1
ATE350016T1 AT02779684T AT02779684T ATE350016T1 AT E350016 T1 ATE350016 T1 AT E350016T1 AT 02779684 T AT02779684 T AT 02779684T AT 02779684 T AT02779684 T AT 02779684T AT E350016 T1 ATE350016 T1 AT E350016T1
Authority
AT
Austria
Prior art keywords
bicalutamid
pharmaceutical composition
composition containing
pharmaceutical
containing bicalutamid
Prior art date
Application number
AT02779684T
Other languages
English (en)
Inventor
Nicola Frances Bateman
Julie Kay Cahill
Neill Hugh Carman
Ian Derek Cockshott
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Application granted granted Critical
Publication of ATE350016T1 publication Critical patent/ATE350016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02779684T 2001-11-16 2002-11-14 Bicalutamid enthaltende pharmazeutische zusammensetzung ATE350016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103839A SE0103839D0 (sv) 2001-11-16 2001-11-16 Pharmaceutical formulation & product

Publications (1)

Publication Number Publication Date
ATE350016T1 true ATE350016T1 (de) 2007-01-15

Family

ID=20286023

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779684T ATE350016T1 (de) 2001-11-16 2002-11-14 Bicalutamid enthaltende pharmazeutische zusammensetzung

Country Status (20)

Country Link
US (1) US20050038111A1 (de)
EP (1) EP1448168B1 (de)
JP (1) JP2005514355A (de)
KR (1) KR20050044468A (de)
CN (1) CN1615122A (de)
AR (1) AR037390A1 (de)
AT (1) ATE350016T1 (de)
AU (1) AU2002343024A1 (de)
BR (1) BR0214135A (de)
CA (1) CA2466986A1 (de)
DE (1) DE60217390T2 (de)
ES (1) ES2278063T3 (de)
IL (1) IL161902A0 (de)
MX (1) MXPA04004591A (de)
NO (1) NO20042502L (de)
SE (1) SE0103839D0 (de)
TW (1) TW200406200A (de)
UY (1) UY27539A1 (de)
WO (1) WO2003043606A1 (de)
ZA (1) ZA200403689B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20032225A3 (cs) * 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
US7226622B2 (en) 2003-09-18 2007-06-05 Boston Scientific Scimed, Inc. Chemoablation of tissue using biodegradable, solid salt dosage forms
CA2554025A1 (en) * 2004-01-28 2005-08-11 Androscience Corporation Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
JP2008511607A (ja) * 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低溶解性薬物および重合体を含む医薬投与剤形
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
WO2006090129A2 (en) * 2005-02-23 2006-08-31 Astrazeneca Ab Bicalutamide for delivering increasing steady state plasma levels
KR20070114343A (ko) * 2005-03-29 2007-12-03 유에스브이 리미티드 비칼루타미드의 제조 방법
US20090291134A1 (en) * 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
PL2252893T3 (pl) * 2008-02-21 2014-03-31 Iris Int Inc Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
TWI673051B (zh) 2012-09-11 2019-10-01 美商梅維森前列腺療法有限責任公司 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CN107049972A (zh) * 2017-03-17 2017-08-18 万特制药(海南)有限公司 一种含有来曲唑固体分散体的分散片及其制备工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating

Also Published As

Publication number Publication date
CA2466986A1 (en) 2003-05-30
AR037390A1 (es) 2004-11-10
BR0214135A (pt) 2004-10-13
JP2005514355A (ja) 2005-05-19
EP1448168B1 (de) 2007-01-03
MXPA04004591A (es) 2004-08-13
US20050038111A1 (en) 2005-02-17
CN1615122A (zh) 2005-05-11
UY27539A1 (es) 2003-07-31
KR20050044468A (ko) 2005-05-12
ZA200403689B (en) 2006-06-28
SE0103839D0 (sv) 2001-11-16
DE60217390T2 (de) 2007-11-15
DE60217390D1 (de) 2007-02-15
WO2003043606A1 (en) 2003-05-30
NO20042502L (no) 2004-08-09
ES2278063T3 (es) 2007-08-01
IL161902A0 (en) 2005-11-20
AU2002343024A1 (en) 2003-06-10
TW200406200A (en) 2004-05-01
EP1448168A1 (de) 2004-08-25

Similar Documents

Publication Publication Date Title
ATE334656T1 (de) Flüssige pharmazeutische zusammensetzung
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60142197D1 (de) Pharmazeutische Zusammensetzung
FI20011478L (fi) Farmaseuttinen koostumus
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
NO20033384L (no) Farmasoytisk formulering
ATE320807T1 (de) Pharmazeutische zusammensetzungen enthaltend tegaserod
NO20035627D0 (no) Farmasöytisk formulering
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
FI20022128L (fi) Farmaseuttinen koostumus
ATE477814T1 (de) Stabile faktor-viii enthaltende pharmazeutische zusammensetzung
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
NO20033073L (no) Farmasöytisk sammensetning inneholdende citalopram
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EP1413314A4 (de) Medizinische zusammensetzungen
NO20041236L (no) Farmasoytisk formulering
FI5468U1 (fi) Farmaseuttinen koostumus
SE0100847D0 (sv) Novel pharmaceutical composition
SE0101171D0 (sv) Pharmaceutical formulation
SE0101325D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties